LEMAITRE VASCULAR INC 8-K

What Happened

• LeMaitre Vascular, Inc. (LMAT) filed an 8-K reporting that director Bridget Ross notified the board on April 8, 2026 that she will not stand for re-election as a Class II director at the Company's 2026 Annual Meeting on June 2, 2026; she will continue to serve until her term expires at that meeting.
• The board nominated David B. Roberts to stand for election as a Class II director at the June 2, 2026 Annual Meeting. On April 9, 2026, Mr. Roberts notified the board he intends to resign as a Class I director at the conclusion of the Annual Meeting, contingent on his election as a Class II director.
• The filing states neither Ms. Ross’s decision nor Mr. Roberts’s conditional resignation is due to any disagreement with the Company. The board thanked Ms. Ross for her service.

Key Details

• Bridget Ross notified the board on April 8, 2026 she will not seek re-election at the June 2, 2026 Annual Meeting.
• David B. Roberts was nominated to the Class II seat; he provided a contingent resignation as a Class I director on April 9, 2026.
• If the changes take effect as described, the board will have seven members after the Annual Meeting: 2 Class I directors, 2 Class II directors, and 3 Class III directors.
• The company’s charter and bylaws allow the board size to be set by board resolution (not fixed).

Why It Matters

• This is a governance change: a board seat turnover and a rebalancing of director class assignments ahead of the annual meeting. Such changes affect board composition and staggered-term structure used in corporate governance.
• The filing reports no disputes or disagreements with management, indicating the changes are procedural rather than conflict-driven.
• There is no financial information or operational guidance disclosed in this 8-K; the item is primarily relevant for shareholders tracking board composition and upcoming director elections.